Hepatitis C Drug Shows Promise Against Deadly Hepatitis E Virus

Hepatitis E virus infects millions globally and kills approximately 70,000 people each year, yet no approved treatments exist. This dangerous gap may soon close thanks to promising research on bemnifosbuvir, a drug currently being tested for hepatitis C treatment.

Researchers from Germany and China screened 500 antiviral compounds to find effective treatments against hepatitis E. They used a modified virus that produces fluorescent signals to track replication in infected cells. Bemnifosbuvir emerged as the top candidate, completely stopping viral reproduction while preserving healthy cell function.

The drug belongs to nucleotide/nucleoside analogues, molecules that mimic genetic building blocks. When hepatitis E tries to replicate, bemnifosbuvir interferes with its genetic machinery, effectively shutting down the process. Follow-up animal studies confirmed the drug reduces both viral activity and liver inflammation without apparent toxicity.

This discovery is particularly significant because bemnifosbuvir is already in clinical trials for hepatitis C, potentially accelerating its availability for hepatitis E. The regulatory pathway could be shorter since safety data already exists. Hepatitis E poses serious risks to immunocompromised individuals, organ transplant recipients, and pregnant women, who can develop chronic infections.

While these results are encouraging, the drug still requires specific testing for hepatitis E treatment. The research team published their findings in the journal Gut, marking an important step toward addressing a major global health threat that has lacked effective interventions for decades.